March 10, 2020 / 10:32 AM / a month ago

BRIEF-Surface Oncology Reports Q4 Loss Per Share Of $0.57

March 10 (Reuters) - Surface Oncology Inc:

* SURFACE ONCOLOGY REPORTS FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2019

* Q4 LOSS PER SHARE $0.57

* Q4 EARNINGS PER SHARE ESTIMATE $-0.58 — REFINITIV IBES DATA

* SURFACE ONCOLOGY - FOLLOWING STRATEGIC RESTRUCTURING IMPLEMENTED IN JAN, CURRENT CASH AND CASH EQUIVALENTS ARE PROJECTED TO FUND CO INTO 2022

* SURFACE ONCOLOGY - AS OF DEC 31, 2019, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $105.2 MILLION, COMPARED TO $158.8 MILLION ON DEC 31, 2018

* SEES INITIAL CLINICAL UPDATES FOR BOTH SRF617 AND SRF388 ANTICIPATED BY END OF 2020

* SURFACE ONCOLOGY - FOLLOWING STRATEGIC RESTRUCTURING IMPLEMENTED IN JAN, CO’S CURRENT CASH & CASH EQUIVALENTS ARE PROJECTED TO FUND CO INTO 2022

* SURFACE ONCOLOGY - ANTICIPATED MILESTONES UNDER NZV930 COLLABORATION, OTHER POTENTIALLY AVAILABLE CAPITAL WOULD EXTEND CASH RUNWAY INTO H2 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below